Application Cycle
June 2025
This technology focuses on developing HIF2 inhibitors to enhance adaptive lung repair for targeted pulmonary fibrosis treatment. The follow-on award will advance this system, which leverages endogenous bioactivation.
Awardee
Primary Department:
Department